Latest Amgen Stories
Data From Phase 3 TESLA Study in Patients With Homozygous Familial Hypercholesterolemia (HoFH) and Phase 2/3 TAUSSIG Study in Patients With Severe Familial Hypercholesterolemia Presented in Late-Breaking
Study Shows Improved Survival Benefit in Panitumumab Arm THOUSAND OAKS, Calif., May 31, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced results from the Phase 2 PEAK study that reinforce
THOUSAND OAKS, Calif., May 30, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at the Jefferies 2014 Global Healthcare Conference at 11:30 a.m.
Editor Note: For more information about this release, please scroll to bottom. On Thursday, May 29, 2014, the NASDAQ Composite ended at 4,247.95, up 0.54%, the Dow Jones
THOUSAND OAKS, Calif., May 29, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will hold a post-American Society of Clinical Oncology (ASCO) summary webcast on Tuesday, June
New Data Reinforces Commitment to Personalized Medicine and Highlights Advances in Immunotherapy Platform THOUSAND OAKS, Calif.
GERMANTOWN, Maryland and HILDEN, Germany, May 23, 2014 /PRNewswire/ -- - Clinically proven companion diagnostic gains U.S.
Vectibix is the First and Only Biologic to Offer Significant Survival Benefit as a First-Line Treatment with FOLFOX Chemotherapy for Patients with Wild-Type KRAS Metastatic Colorectal Cancer THOUSAND
Early Data Demonstrate Anti-TSLP Therapy Reduces Early and Late Asthmatic Responses and Several Key Inflammatory Markers THOUSAND OAKS, Calif., May 20, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN)
THOUSAND OAKS, Calif., May 15, 2014 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced voting results from the Company's Annual Meeting of Stockholders, held in Westlake Village, Calif.
- One who brings meat to the table; hence, in some countries, the official title of the grand master or steward of the king's or a nobleman's household.